Aquestive Therapeutics, Inc. (AQST)

NGM – Цена в реальном времени. Валюта: USD

4.39

-0.08 (-1.68%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

4.40

+0.01 (0.23%)

После закрытия: Jun 26, 2026, 7:58 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Aquestive Therapeutics, Inc. (AQST)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Aquestive Therapeutics, Inc. (AQST)

Aquestive Therapeutics, Inc. (AQST) Q1 2026 Earnings Call Transcript

Aquestive Therapeutics Q1 Earnings Call Highlights

Compared to Estimates, Aquestive Therapeutics (AQST) Q1 Earnings: A Look at Key Metrics

Aquestive Therapeutics (AQST) Reports Q1 Loss, Beats Revenue Estimates

Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree

Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET

Видео

No Data

Пресс-релизы

Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree

AQST FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026

Bronstein, Gewirtz & Grossman LLC Urges Aquestive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Search stocks

Aquestive Therapeutics, Inc. (AQST)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Aquestive Therapeutics, Inc. (AQST)

Aquestive Therapeutics, Inc. (AQST) Q1 2026 Earnings Call Transcript

Aquestive Therapeutics Q1 Earnings Call Highlights

Compared to Estimates, Aquestive Therapeutics (AQST) Q1 Earnings: A Look at Key Metrics

Aquestive Therapeutics (AQST) Reports Q1 Loss, Beats Revenue Estimates

Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree

Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET

Видео

No Data

Пресс-релизы

Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree

AQST FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026

Bronstein, Gewirtz & Grossman LLC Urges Aquestive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm